Previous 10 | Next 10 |
home / stock / phmmf / phmmf news
MADRID , June 11, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Argentina , Bolivia , Brazi...
MADRID , June 5, 2018 /PRNewswire/ -- Abstract #8018 The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented . Of the 84 patients treated in the comparator arm (dexamethasone as a ...
MADRID , June 4, 2018 /PRNewswire/ -- Abstract #8570 The phase II basket trial, which began recruiting 15 patients with recurrent small-cell lung cancer, was increased to target enrolment of 100 after obtaining a positive response. In a total of 61 patients, an object...
MADRID , May 29, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre ® (lurbinectedin, PM1183) in com...
MADRID , May 17, 2018 /PRNewswire/ -- During the Congress of the American Society of Clinical Oncology (ASCO) that will be held form the 1 st to the 5 th of June in Chicago ( USA ), PharmaMar will present the data obtained from various clinical studies of the molecules Yondelis ...
MADRID , May 7, 2018 /PRNewswire/ -- • The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80% [i] . • The ARVO meeting has considered the poster presentation to be of scientific interest, contributing t...
MADRID , May 4, 2018 /PRNewswire/ -- Within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), that has been held from the 29 th of April to the 3 rd of May in Honolulu ( Hawaii ), Sylentis, pharmaceutical company belonging to the P...
MADRID , May 3, 2018 /PRNewswire/ -- The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome [i] Sylentis, Pharmaceutical Company belonging to the ...
MADRID , April 26, 2018 /PRNewswire/ -- Sylentis, Pharmaceutical Company belonging to PharmaMar Group (MCE: PHM) will present new results on three ophthalmological compounds for the treatment of dry eye syndrome, macular degeneration associated to age, administered topically, and also f...
MADRID , April 17, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells. Under the title " eEF1A2 interacts with and inhibits PKR to enhance canc...
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Ebix Inc. (EBIXQ) is expected to report for Q1 2024 Amesite Inc. (AMST) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.68 for Q1 2025 Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A) (WDH) is expected to repo...
TDCX Inc. American Depositary Shares each representing one Class A (TDCX) is expected to report for Q1 2024 nCino Inc. (NCNO) is expected to report $0 for Q1 2025 SK Telecom Co. Ltd. (SKM) is expected to report for Q1 2024 Redeia Corporacion S.A. ADR (RDEIY) is expected to report for ...